(0.27%) 5 475.09 points
(0.13%) 39 170 points
(0.83%) 17 879 points
(0.16%) $83.51
(-0.20%) $2.47
(0.15%) $2 342.50
(0.48%) $29.76
(0.45%) $993.10
(0.06%) $0.931
(0.13%) $10.66
(0.04%) $0.791
(0.00%) $86.75
Live Chart Being Loaded With Signals
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa...
Stats | |
---|---|
Today's Volume | 119 736 |
Average Volume | 740 433 |
Market Cap | 172.04M |
EPS | $-1.160 ( Q1 | 2024-05-15 ) |
Next earnings date | ( $-0.290 ) 2024-08-13 |
Last Dividend | $3 706.25 ( 2000-03-31 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.330 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00800 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-18 | Alvino Mark | Sell | 25 890 | Common Stock |
2024-06-18 | Silverstein Christine Berni | Sell | 25 821 | Common Stock |
2024-06-05 | Vazzano Joseph Walter | Sell | 16 408 | Common stock |
2024-06-05 | Seshadri Vishwas | Sell | 38 621 | Common Stock |
2024-06-05 | O'malley Brendan M. | Sell | 10 951 | Common stock |
INSIDER POWER |
---|
90.61 |
Last 97 transactions |
Buy: 7 475 441 | Sell: 647 913 |
Volume Correlation
Abeona Therapeutics Inc Correlation
10 Most Positive Correlations | |
---|---|
OZEM | 1 |
NBBK | 0.952 |
MAMA | 0.946 |
EVCGX | 0.934 |
BUJA | 0.919 |
MMUKX | 0.918 |
PRE | 0.915 |
HUMA | 0.914 |
MICFX | 0.912 |
MCHFX | 0.912 |
10 Most Negative Correlations | |
---|---|
IIMFX | -0.942 |
INDH | -0.917 |
NWGL | -0.89 |
QREARX | -0.89 |
HTOOW | -0.885 |
IVP | -0.881 |
AONC | -0.877 |
OPTZ | -0.875 |
BAER | -0.874 |
APLM | -0.873 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Abeona Therapeutics Inc Correlation - Currency/Commodity
Abeona Therapeutics Inc Financials
Annual | 2023 |
Revenue: | $3.50M |
Gross Profit: | $302 000 (8.63 %) |
EPS: | $-2.53 |
FY | 2023 |
Revenue: | $3.50M |
Gross Profit: | $302 000 (8.63 %) |
EPS: | $-2.53 |
FY | 2022 |
Revenue: | $1.41M |
Gross Profit: | $964 000 (68.18 %) |
EPS: | $-4.05 |
FY | 2021 |
Revenue: | $3.00M |
Gross Profit: | $3.00M (100.00 %) |
EPS: | $-21.57 |
Financial Reports:
No articles found.
Abeona Therapeutics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $3 706.25 | 2000-03-31 |
Last Dividend | $3 706.25 | 2000-03-31 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $3 706.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2000 | $3.00 | 0.03% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
31 Mar 2000 | $3 706.25 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -12.12 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.024 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -8.21 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 5.61 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.46 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.505 | 1.500 | 2.75 | 4.12 | [0.2 - 2] |
debtRatioTTM | 0.256 | -1.500 | 5.74 | -8.61 | [0 - 0.6] |
interestCoverageTTM | -39.79 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.457 | 2.00 | -0.486 | -0.971 | [0 - 30] |
freeCashFlowPerShareTTM | -1.488 | 2.00 | -0.744 | -1.488 | [0 - 20] |
debtEquityRatioTTM | -2.15 | -1.500 | -8.61 | 10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.520 | 1.000 | 4.66 | 4.66 | [0.2 - 0.8] |
operatingProfitMarginTTM | -7.98 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -2.08 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0845 | 0.800 | -2.77 | -2.22 | [0.5 - 2] |
Total Score | -4.38 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -1.511 | 1.000 | -0.254 | 0 | [1 - 100] |
returnOnEquityTTM | -8.21 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.488 | 2.00 | -0.496 | -1.488 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.457 | 2.00 | -0.486 | -0.971 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0700 | 1.500 | -2.87 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -6.29 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.65 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators